Navigate orthopedic clinical trials in Guatemala: 4 planning steps

Four sponsor planning steps for an orthopedic device study in Guatemala: device file versus Phase I, ethics, the statutory clock, and activation.

Regulatory sources checked November 7, 2026. General sponsor guidance, not legal advice or an approval guarantee.

This page is for sponsors planning an orthopedic device investigation in Guatemala. It is not a patient advertisement, and it does not claim that participants are untreated, easier to enroll, or less expensive than elsewhere.

An orthopedic implant or instrument is assessed as a medical-device investigation under section 43 of Agreement 206-2021, not as a drug Phase I file under section 45.1. MSPAS through DRCPFA is the competent authority. A commercial registration under Acuerdo Gubernativo 712-99 and Norma Técnica 37 does not authorize the investigation.

1. Confirm that the file is a device investigation

Section 43 asks for device information, manufacturer and performance or safety documentation, manufacturing-quality evidence, relevant in-vitro and in-vivo evidence, investigator information, and a copy of the trial insurance policy (section 43.8). The evidence that is appropriate depends on the device and the investigation. ISO 14155 can inform device good-clinical-practice planning. This page does not claim that the agreement expressly adopts it.

Do not assume every orthopedic product qualifies, and do not treat prior foreign marketing approval as a universal entry ticket. Product eligibility is study-specific. Drug Phase I has its own list in section 45.1, including prior animal toxicity and a Phase I-capable facility.

2. Obtain ethics approval before DRCPFA

Sections 37.8 and 42 put ethics approval before the Department sees the application. There is no single national meeting calendar to plan around. Check the committee’s current authorization, relevant expertise, and its own calendar. Section 38.7 requires each committee to publish, on request, its procedures, meeting frequency, and maximum response time.

The protocol must be in Spanish. The investigator brochure may be in the original language with a Spanish summary. Confirm translation and legalization for the rest of the dossier instead of assuming every document is bilingual. Consent translation does not by itself prove understanding.

3. Use the complete-file clock, not a startup slogan

Section 47 allows up to 30 business days after complete documentation is received. A query gives the applicant 15 business days to respond, and the text then allows 15 business days for the decision after that information arrives. Those periods are not an ethics clock, not a measured average, and not a count from protocol finalization to first procedure. The agreement does not publish a fixed startup length measured in weeks.

4. Plan insurance, import, and activation on their own

Insurance must be in place before the trial starts (section 11), and the device application includes the policy (section 43.8). Section 103.1 says the sponsor does not supply investigational product to the institution until the required ethics and Department documentation is in hand. Contracts, training, storage, accountability, and site readiness are separate from both the ethics calendar and the 30-business-day clock. Section 48 provides a one-year authorization where that term applies.

Confirm current forms, including F-EC-a-01, on the MSPAS forms portal before filing. The portal has listed version 04-2025, effective 3 November 2025. That version still has to be confirmed on the day you file.

The study-specific MSPAS pathway, including Phase I and device-investigation requirements, is on clinical trials in Guatemala.

Commercial device registration is a different file: Guatemala MSPAS registration and how to register a medical device in Guatemala. Acuerdo Gubernativo 712-99 and Norma Técnica 37 are a commercial framework, not a study permit.

Primary sources

Contact bioaccess® to request a Guatemala feasibility assessment. Bring the product description, development stage, preclinical evidence, proposed population, procedures, and follow-up.

Frequently asked questions

Is an orthopedic study a Phase I drug trial?

No. Use the device-investigation dossier in section 43. Drug Phase I requirements are in section 45.1 and apply to a drug study.

Does Guatemala promise a 12-to-15-week start?

No. Plan ethics review, the complete-file authority clock, queries, import, and activation as separate steps.

Does commercial device registration authorize the orthopedic investigation?

No. Selling authorization and investigational authorization are different MSPAS files.

← Back to Blog · Contact bioaccess®